Evidence
Ageing Res Rev. 2023 Dec 6:102161. doi: 10.1016/j.arr.2023.102161. Online ahead of print.
ABSTRACT
Recent trials with monoclonal antibodies targeting amyloid-β (Aβ) in Alzheimer’s disease (AD) have sparked a renewed interest in disease-modifying therapies. Despite their promise, these trials leave the issue open and posit some doubts about the validity of the Amyloid Cascade Hypothesis (ACH). While some scores of neurocognitive tests improved upon treatment, real-world clinical benefits were minimal. This Viewpoint discusses additional, often overlooked findings from these trials. We also emphasize the multifactorial nature of AD and the need for a broader research perspective beyond the simplistic disease model provided by the ACH.
PMID:38065226 | DOI:10.1016/j.arr.2023.102161
Add to Google Keep
Estimated reading time: 2 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Once upon a time, the Amyloid Cascade Hypothesis
🌐 90 Days
VR Related Evidence Matrix
- Alzheimer's Drugs APPlication for Down syndrome?
- Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease
- Types of memory, dementia, Alzheimer's disease, and their various pathological cascades as targets for potential pharmacological drugs
- Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review
- Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review
- Minimal clinically important difference in Alzheimer's disease: Rapid review
- Passive immunotherapy for Alzheimer's disease: challenges & future directions
- The vascular contribution of apolipoprotein E to Alzheimer's disease
- Targeting terminal pathway reduces brain complement activation, amyloid load and synapse loss, and improves cognition in a mouse model of dementia
- Quantitative Brain Amyloid PET
- Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities
- Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study
- NLRP3 inflammasome signalling in Alzheimer's disease
- Deep learning to predict rapid progression of Alzheimer's disease from pooled clinical trials: A retrospective study
- Using Drosophila amyloid toxicity models to study Alzheimer's disease
- Is Alzheimer disease a disease?
- Lecanemab Questions
- The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials
- Subsequent correlated changes in complement component 3 and amyloid beta oligomers in the blood of patients with Alzheimer's disease
- Artificial intelligence and open science in discovery of disease-modifying medicines for Alzheimer's disease
- Multiple system atrophy with amyloid-b-predominant Alzheimer's disease neuropathologic change
- Addressing the Discrepancies Between Animal Models and Human Alzheimer's Disease Pathology: Implications for Translational Research
- Sonic Hedgehog Signalling Pathway Contributes in Age-Related Disorders and Alzheimer's Disease
- Clinical Arterial Spin-Labeling MR Imaging to Screen for Typical and Atypical Neurodegenerative Disease in the New Era of Alzheimer Treatment
- Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease
- 9-cis beta-carotene-enriched diet significantly improved cognition and decreased Alzheimer's disease neuropathology and neuroinflammation in Alzheimer's disease-like mouse models
- 9-cis beta-carotene-enriched diet significantly improved cognition and decreased Alzheimer's disease neuropathology and neuroinflammation in Alzheimer's disease-like mouse models
- Imaging Amyloid-β Membrane Interactions: Ion-Channel Pores and Lipid-Bilayer Permeability in Alzheimer's Disease
- Characterisation of premature cell senescence in Alzheimer's disease using single nuclear transcriptomics
- Brain structural indicators of beta-amyloid neuropathology
- Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease
- A multimodal deep learning approach for the prediction of cognitive decline and its effectiveness in clinical trials for Alzheimer's disease
- Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles
- Ready or Not: A Conceptual Model of Organizational Readiness for Embedded Pragmatic Dementia Research
- Potential Convergence of Olfactory Dysfunction in Parkinson's Disease and COVID-19: The Role of Neuroinflammation
- Pragmatic clinical trials to advance research in children and adolescents with eating disorders
- Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients
- Treatment of Alzheimer's Disease in the New Era of Monoclonal Antibodies Against Cerebral Amyloid-β: Pharmacological Prescription and Knowledge in Argentina
- Divergent Age-Dependent Conformational Rearrangement within Ab Amyloid Deposits in APP23, APPPS1, and AppNL-F Mice
- The seeds of its regulation: natural antisense transcripts as single-gene control switches in neurodegenerative disorders
- Insights into amyloid precursor protein target through PPI network analysis
- Production and characterization of novel monoclonal antibodies against pathological human TDP-43 proteins
- The efficacy of dyadic interventions for community-dwelling people with dementia and their caregivers: a systematic review and meta-analysis
- Mechanisms of pain in aging and age-related conditions: focus on caregivers
- Predicting functional decline in aging and Alzheimer's disease with PET-based Braak staging
- Latest advances and clinical application prospects of resveratrol therapy for neurocognitive disorders
- Contribution of Global Amyloid-PET Imaging for Predicting Future Cognition in the MEMENTO Cohort
- Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of AB amyloidosis
- Outcome Reporting Bias in Clinical Trials Researching Disease-Modifying Therapy in Patients With Multiple Sclerosis
- Effects of SPI1-mediated transcriptome remodeling on Alzheimer's disease-related phenotypes in mouse models of AB amyloidosis
- Bacteroidota inhibit microglia clearance of amyloid-beta and promote plaque deposition in Alzheimer's disease mouse models
- Real-world persistence of multiple sclerosis disease-modifying therapies
- Donanemab in Japanese Patients with Early Alzheimer's Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial
- Systemic inflammation in Ab1-40-induced Alzheimer's disease model: New translational opportunities
- Genomic stress and impaired DNA repair in Alzheimer disease
- The clinical importance of suspected non-Alzheimer disease pathophysiology
- Exploring the potential of quercetin in Alzheimer's Disease: Pharmacodynamics, Pharmacokinetics, and Nanodelivery systems
- Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease
- Cognition and Amyloid-b in Older Veterans: Characterization and Longitudinal Outcomes of Data-Derived Phenotypes
- Effectiveness of cognitive stimulation therapy (CST) for mild to moderate dementia: A systematic literature review and meta-analysis of randomised control trials using the original CST protocol
- Divergent Associations of Slow-Wave Sleep versus Rapid Eye Movement Sleep with Plasma Amyloid-Beta
- Cognition and Amyloid-b in Older Veterans: Characterization and Longitudinal Outcomes of Data-Derived Phenotypes
- Navigating the metabolic maze: anomalies in fatty acid and cholesterol processes in Alzheimer's astrocytes
- Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease
Evidence Blueprint
Once upon a time, the Amyloid Cascade Hypothesis
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Once upon a time, the Amyloid Cascade Hypothesis
🌐 365 Days
VR Related Evidence Matrix
- Anti-amyloid antibody treatments for Alzheimer's disease
- Alzheimer's Drugs APPlication for Down syndrome?
- The supersaturation perspective on the amyloid hypothesis
- Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis
- Estimating demand for potential disease-modifying therapies for Alzheimer's disease in the UK
- Navigating the Dementia Landscape: Biomarkers and Emerging Therapies
- How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease?
- Recent Advancement in Therapeutic Strategies for Alzheimer's Disease: Insights from Clinical Trials
- GLP-1/Sigma/RAGE Receptors: An evolving picture of Alzheimer's Disease pathology and treatment
- How donanemab data address the coverage with evidence development questions
- A data-driven study of Alzheimer's disease related amyloid and tau pathology progression
- Treatment of the CRND8 mouse model for cerebral amyloid angiopathy, exhibited increased levels of neuron specific enolase in brain tissue following long-term treatment with a modified C5a receptor agonist, accompanied by improved cognitive function
- Transcending the amyloid-beta dominance paradigm in Alzheimer's disease: An exploration of behavioural, metabolic, and gut microbiota phenotypes in 5xFAD mice
- Cuprizone drives divergent neuropathological changes in different mouse models of Alzheimer's disease
- Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease
- Passive tau-based immunotherapy for tauopathies
- New horizons in the diagnosis and management of Alzheimer's Disease in older adults
- Types of memory, dementia, Alzheimer's disease, and their various pathological cascades as targets for potential pharmacological drugs
- Understanding the mechanisms of disease modifying effects of aerobic exercise in people with Alzheimer's disease
- A peripheral signature of Alzheimer's disease featuring microbiota-gut-brain axis markers
- Targeted examination of amyloid beta and tau protein accumulation via positron emission tomography for the differential diagnosis of Alzheimer's disease based on the A/T(N) research framework
- Lithium: An Old Drug for New Therapeutic Strategy for Alzheimer's Disease and Related Dementia
- Trial of Solanezumab in Preclinical Alzheimer's Disease
- Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review
- Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review
- Minimal clinically important difference in Alzheimer's disease: Rapid review
- Controversial Past, Splendid Present, Unpredictable Future: A Brief Review of Alzheimer Disease History
- Radiotherapy in Alzheimer's Disease: A Systematic Review
- Passive immunotherapy for Alzheimer's disease: challenges & future directions
- Utility of amyloid PET Imaging in a Memory Clinic
- Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes
- The vascular contribution of apolipoprotein E to Alzheimer's disease
- Alzheimer's Disease: Novel Targets and Investigational Drugs for Disease Modification
- Longitudinal changes in hippocampal texture from healthy aging to Alzheimer's disease
- Targeting terminal pathway reduces brain complement activation, amyloid load and synapse loss, and improves cognition in a mouse model of dementia
- Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease: Emerging Issues in Neurology
- Quantitative Brain Amyloid PET
- Post-disclosure distress among racial and ethnic groups in a preclinical AD trial
- Molecular pathology of neurodegenerative diseases by cryo-EM of amyloids
- Validating blood tests as a possible routine diagnostic assay of Alzheimer's disease
- Alzheimer's Disease: The Past, Present, and Future of a Globally Progressive Disease
- Lecanemab: Appropriate Use Recommendations
- Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: a systematic review and network meta-analysis
- Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology
- Development of small-molecule Tau-SH3 interaction inhibitors that prevent amyloid-β toxicity and network hyperexcitability
- Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities
- Apolipoprotein E Genetic Testing in a New Age of Alzheimer Disease Clinical Practice
- Lewy body pathology modifies risk factors for cerebral amyloid angiopathy when comorbid with Alzheimer's disease pathology
- Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study
- Ischemia-Reperfusion Programming of Alzheimer's Disease-Related Genes-A New Perspective on Brain Neurodegeneration after Cardiac Arrest
- NLRP3 inflammasome signalling in Alzheimer's disease
- Myelin dysfunction drives amyloid-β deposition in models of Alzheimer's disease
- Deep learning to predict rapid progression of Alzheimer's disease from pooled clinical trials: A retrospective study
- Using Drosophila amyloid toxicity models to study Alzheimer's disease
- Prevalence, distribution, and severity of cerebral amyloid angiopathy differ between Lewy body diseases and Alzheimer's disease
- Underserved groups in dysphagia intervention trials in Parkinson's disease: A scoping review
- The elusive role of herpesviruses in Alzheimer's disease: current evidence and future directions
- Dihydroquercetin as a systemic neuroprotector for the prevention and treatment of β-amyloid-associated brain diseases
- Is Alzheimer disease a disease?
- Intranasal insulin intake and exercise improve memory function in amyloid-β induced Alzheimer's-like disease in rats: Involvement of hippocampal BDNF-TrkB receptor
- Lecanemab Questions
- ATN Classification and Clinical Progression of the Amyloid-Negative Group in Alzheimer's Disease Neuroimaging Initiative Participants
- The link between Alzheimer disease and metabolic syndrome: A mutual relationship and long rigorous investigation
- Harmonization of CSF and imaging biomarkers for Alzheimer's disease: Need and practical applications for genetics studies and preclinical classification